CELLUGY®’s Post

This week on Careers in Discovery, we’re joined by Rodrigo Santos, CTO of clock.bio, a company pushing the boundaries of cellular rejuvenation to tackle age-related diseases. Rodrigo shares the fascinating work happening at clock.bio, including their hypothesis-free approach to uncovering rejuvenation factors and the creation of their “Atlas of Rejuvenation Factors.” We also got to hear about Rodrigo’s incredible journey - from growing up in a small farming village in Portugal to leading cutting-edge biotech companies - all driven by his passion for cellular plasticity and the transformative potential of Yamanaka factors. Along the way, he reflects on the lessons he’s learned, balancing science and business, and why emphasis on execution is key. Join us as we explore the science of rejuvenation, the innovation behind it, and the mindset needed to succeed in this ever-evolving field. #Rejuvenation #Innovation #Biotech

We are proud to announce our investment in Biomemory through their $18M Series A funding round! As Next Sequence® with Loretta TIOIELA 🇺🇦, we're thrilled to support Erfane Arwani and his exceptional team in their mission to revolutionize data storage through groundbreaking DNA technology. Why Biomemory? Their innovative approach to molecular data storage promises unprecedented storage density - imagine preserving humanity's entire digital legacy in just one data center rack. With the data storage market projected to reach $390B by 2028, Biomemory's sustainable solution couldn't come at a better time. We're excited to join forces with Crédit Mutuel Innovation, Bpifrance, Blast Club, SORBONNE VENTURE (AUDACIA), ADNEXUS, Paris Business Angels and Groupe Prunay! to back this transformative technology. Looking forward to supporting Biomemory as they complete their first-generation data storage appliance and forge new partnerships in the industry. The future of data storage is molecular, and we're proud to be part of this journey! 🧬 #DataStorage #DNATechnology #Molecular #DNAStorage #Deeptech

🎉 Newlab Member News Alert! 🎉 Congratulations to Caladan Bio on the launch of The Caladan 250 and on securing a $5M seed round led by Twelve Below with participation from Lerer Hippeau, Collaborative Fund, Wireframe Ventures, Ritual Capital and Factorial! About the Caladan 250: The Caladan 250 is a high throughput benchtop bioreactor system designed to increase experimentation throughput and enhance data capture - all while leveraging AI and ML. "As the tools to edit cells become commonplace, the focus needs to shift to optimizing biomanufacturing. At Caladan, we believe that for synthetic biology companies, the process is the product," says Michael Kobida, Co-Founder and CEO of Caladan Bio. Join us in celebrating this milestone achievement with Caladan Bio! Learn how you can join Newlab’s community of founders changing the world: https://lnkd.in/gbNRFZs6 Read more about Caladan's last round here: https://lnkd.in/gh8PxTgB

This March, I'm speaking at Central European BioForum. Those who follow our Viseven journey probably know that in 2019, we took a great focus on global expansion. Ever since came riveting times of new challenges, lessons, failures, and successes. During the panel discussion "How to enter the US market?" I'll gladly share how Viseven managed the intricacies of this global expansion and cooperation with bio-related companies. #CEBioForum2024 is said to be the place where you meet key players in biotech in CEE in one spot in order to find business development opportunities. Together with Nataliya Kulyba, Maciej Najdzion, Oleksandra Yashyna (Zikh), and Dominika Sosnowska, we're looking forward to this opportunity. Meanwhile, let's connect! #martech #biotech #globalbusiness

Thanks to all that joined the closing panel session of #BioEquityEurope as the conference wrapped up by looking to the future and heard from Campbell Stewart of Novo Holdings, Therese Liechtenstein of M Ventures , Gabriela Ecco of +ND Capital and Anne Grahl of Pureos Bioventures We spoke about: 💰 the role of investors ✅how we can support portfolio companies to break out from the noise, and to navigate challenges 🤖 the investment opportunities that are created by enabling technologies such as AI and novel research methods that are unlocking new insights into biology 🧬 But, how investment fundamentals in biotech remain the same 🧪 And, that the key to winning investor interest is to have breakthrough science that ignites our curiosity enough to partner with a team for the long term

Paris-based Biomemory secures $18M in Series A funding led by Crédit Mutuel Innovation, with contributions from Blast, Bpifrance (through the Deep Tech 2030 fund), Paris Business Angels, and several others. Under the leadership of CEO Erfane Arwani, Biomemory is pioneering DNA-based, bio-sourced data storage solutions. FinSMEs https://lnkd.in/gisrv7EW #lifesciences

#BIO is one of the biggest conferences in the scientific world — and brings together a massive community of folks tackling some of the most complex problems on this planet. It reminds me how transformative community and storytelling are in the biotech space. After 10+ years navigating the intersections of #biotech and #deeptech, I've learned that making complex innovations accessible and engaging can be the difference between success and its opposite. We’ve been working with the great folks at Decoding Bio to tell the story about what it means to not just build community around biological initiatives, but to write and push the story forward in surprising ways. A space that exemplifies the power of inclusivity in science. It's a resource that lowers barriers, allowing more people to engage with the latest research and developments. This kind of accessibility is what we strive for at Bunsen, where we help biotech companies tell their stories with clarity and purpose. I'm eager to connect with innovators looking to amplify their impact. If you’re at #BIO24 and want to discuss how your design and story can captivate and inform, let’s chat. Bunsen is all about tailor-fitting narratives that take your company’s story to the next level.

Introducing Nature’s Superpower. GreenLight Biosciences faced a challenge to communicate the power and potential of its innovations. We tackled this with a new brand idea, ‘Nature’s Superpower’, which conveys the everyday wonder of RNA. Through it, a new story emerges, revealing how GreenLight’s disruptive technology is rooted in nature itself. Our new brand system transforms an abstract scientific concept into a natural marvel with real-world benefits for people, plant and planet. So GreenLight can scale its vision of a healthier world for investors and the public alike. https://lnkd.in/d2GBvXDM

Come connect with me and my DC team today at the Bio Innovation Conference! Stop by our booth (#11) to learn how PwC supports emerging growth companies and leading biotechs. #MDLSBioInnovation

💥BOOM!💥 Right after announcing our investments in #deeptech Entalpic and #fintech Jump, we’re back at it again—this time backing another #deeptech: welcome, InSpek! InSpek just raised €3.5M to build the next generation of biological and chemical monitoring systems using integrated photonics, and we’re thrilled to be co-leading this round with Wind, alongside historical investor Quantonation. So, what’s the big deal? From creating vaccines, therapeutic proteins for diseases like cancer and diabetes, to treating waste - bioprocesses are at the heart of today’s bioeconomy. InSpek’s miniaturized sensors provide real-time, non-invasive process monitoring of critical bioprocess parameters—think temperature, acidity, oxygen levels—all the essentials, reducing inefficiencies and unlocking new possibilities for scaling production. Big kudos Jérôme, Ivan-Lazar and InSpek team 🙌 More here https://lnkd.in/egTDjUYr